Sign In
Buy VCNX
$0.85
+0.0181 (+2.19%)
At Close: Jul 31, 2026
Vaccinex, Inc. to Present at the Society for Immunotherapy of Cancer's (SITC) 36th Annual Meeting
08:00am, Wednesday, 10'th Nov 2021
In-person and virtual Presentation: November 10-14th, 2021 In-person and virtual Presentation: November 10-14th, 2021
Vaccinex, Inc. to Present at the 12th Annual Jefferies London Healthcare Conference
08:00am, Thursday, 04'th Nov 2021
Virtual Dates: November 18 th – 19 th , 2021
Vaccinex to Present at the Virtual Huntington's Study Group Meeting on November 4-6, 2021
08:00am, Monday, 01'st Nov 2021
Presentation to highlight expanded post-hoc subgroup analysis of the SIGNAL Phase 2 Huntington's Disease (HD) trial suggesting a cognitive benefit in patients with mildly advanced disease Presentation
Vaccinex to Present at the Oppenheimer & Co. Inc. Fall Healthcare Life Sciences and MedTech Summit
08:00am, Friday, 17'th Sep 2021
ROCHESTER, N.Y., Sept. 17, 2021 (GLOBE NEWSWIRE) -- Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology Company pioneering a differentiated approach to treating neurodegenerative disease and
Vaccinex Reports Second Quarter 2021 Financial Results and Provides Corporate Update
08:15am, Monday, 16'th Aug 2021
Patients are currently being screened and enrolled in two studies of pepinemab as monotherapy in Alzheimer's disease and in combination with KEYTRUDA® in Metastatic Head and Neck Squamous Cell Carcin
Company plans to activate at least 13 clinical sites for Alzheimer's study and 18 clinical sites for head and neck cancer across the United States Company plans to activate at least 13 clinical sites
Vaccinex Reports First Quarter 2021 Financial Results and Provides Corporate Update
08:15am, Monday, 17'th May 2021
Initiated Phase 2 study of pepinemab in combination with KEYTRUDA® in advanced, recurrent or metastatic head and neck cancer
Vaccinex Reports Fourth Quarter 2020 Financial Results and Provides Corporate Update
08:05am, Tuesday, 16'th Mar 2021
Reported top-line results from Phase 2 SIGNAL study that indicates potential cognitive benefit of pepinemab in neurodegenerative disease. New Alzheimer's study expected to begin enrollment in Q2
VCNX Stock Price Increased Over 18% Intraday: Why It Happened
10:19am, Monday, 22'nd Feb 2021
The stock price of Vaccinex, Inc. (Nasdaq: VCNX) increased over 18% during intraday trading today. This is why it happened.
Why Novavax, Vaccinex, Evolus Are Trading Higher Today
12:46pm, Friday, 19'th Feb 2021
Novavax (NASDAQ: NVAX) shares are trading higher Friday after the company announced a Memorandum of Understanding with Gavi to provide 1.1 billion cumulative doses of NVX-CoV2373. Novavax is a biotech
Vaccinex stock soars 223% on partnership deals using its antibody discovery platform (VCNX)
12:21pm, Friday, 19'th Feb 2021
Vaccinex stock rocketed up more than 200% Friday, propelled by two collaboration deals centered on using the biotech company's antibody discovery platform. Vaccinex, which focuses on cancer and neur
Vaccinex's stock soars toward record gain on record volume after deals with 'prominent' drug makers
12:20pm, Friday, 19'th Feb 2021
Shares of Vaccinex Inc. soared toward a record rally on record volume Friday, after the biotechnology company announced the signing of multiple-project deals with two "prominent" pharmaceutical compan
VCNX Stock: 11 Things to Know About Vaccinex and the Deals That Have Shares Soaring
10:36am, Friday, 19'th Feb 2021
Vaccinex (VCNX) stock is rocketing higher on Friday after following an announcement about multi-project deals with two comapnies. The post VCNX Stock: 11 Things to Know About Vaccinex and the Deals Th
Why Vaccinex Shares Are Rallying
10:23am, Friday, 19'th Feb 2021
Shares of micro-cap biopharma Vaccinex Inc (NASDAQ: VCNX) were trading higher Friday on above-average volume. Rochester, New York-based Vaccinex, which focuses on therapies for cancer and neurodegener
VCNX Stock Price Increases Over 60% Pre-Market: Why It Happened
08:47am, Friday, 19'th Feb 2021
The stock price of Vaccinex Inc (Nasdaq: VCNX) is trading at over 60% pre-market. This is why it happened.
